Latest Conference Articles

The frequency of moderate to severe cytokine release syndrome was reduced in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a BCMA-targeted CAR T-cell therapy, according to findings presented at the European Hematology Association 2021 Virtual Congress.

With longer follow-up, significant responses were still observed with the BTK inhibitor zanubrutinib as a single agent in patients with relapsed or refractory chronic lymphocytic leukemia in the phase 2 BGB-3111-205 trial.

Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.

Following rituximab resistance, the combination of lenalidomide and rituximab led to durable improvements in outcome for patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas, even after 10 years of follow-up, according to long-term results presented at the European Hematology Association 2021 Congress.

A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials, according to a poster presented at the European Hematology Association 2021 Virtual Congress.

With further follow-up from the phase 3 CLL14 trial, the median progression-free survival was still reached with the fixed-dose regimen of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.

Without requiring red blood cell transfusions, luspatercept-aamt led to a mean increase in hemoglobin from baseline levels in 77.1% of patients compared with in 0% treated with placebo in patients with non-transfusion–dependent β-thalassemia in the phase 2 BEYOND trial, according to a presentation during the European Hematology Association 2021 Virtual Congress.

The frequency of neurologic toxicities from ciltacabtagene autoleucel can be reduced with management strategies for patients with relapsed or refractory multiple myeloma treated with the chimeric antigen receptor T-cell therapy, findings from CARTITUDE-2 show.

A combination of zandelisib and zanubrutinib induced significant responses, including several complete responses in patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell lymphomas in a phase 1b study, the results of which were presented during the 2021 European Hematology Association Annual Congress.

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.

A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.

Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.

Real world data looking at the use of the recently approved CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel show that patients are receiving it prior to failing treatments and that 1 in 6 patients were experiencing relapse after treatment.

Patients with triple-class exposed relapsed or refractory multiple myeloma demonstrated greater efficacy in terms of response and survival from treatment with ciltacabtagene autoleucel in comparison with the standard of care (SOC) in the CARTITUDE-1 trial, according to findings presented at the 2021 EHA Congress.

A fixed duration of ibrutinib plus venetoclax led to a significant progression-free survival benefit over chlorambucil plus obinutuzumab as frontline treatment in patients with chronic lymphocytic leukemia, according to a primary analysis of the phase 3 GLOW study presented at the European Hematology Association 2021 Virtual Congress.

Daratumumab added to the standard of care with lenalidomide and dexamethasone continued to show a survival benefit over Rd alone in patients with transplant-ineligible, newly diagnosed multiple myeloma after almost 5 years of follow-up, updated results from the phase 3 MAIA trial show.

Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.

Interim results from the phase 3 ALPINE trial suggest that treatment with zanubrutinib may be superior to treatment with ibrutinib for patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Outcomes for patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody improved with the use of ciltacabtagene autoleucel as compared with conventional therapies, according to findings from propensity score–matched analyses of the CARTITUDE-1 and MAMMOTH studies.

An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.

Results of a single-arm phase 2 study of regorafenib plus nivolumab in patients with mismatch repair–proficient/microsatellite stable colorectal cancer found a discrepancy in efficacy between the Japanese and North American Population.

More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.

Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.

Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.

In patients with relapsed/refractory multiple myeloma, treatment with higher doses of subcutaneous elranatamab was found to be effective, according to findings from a phase 1 clinical trial.

Few patients required subsequent anticancer therapies with the combination of lenvatinib (Lenvima) plus everolimus versus sunitinib for advanced renal cell carcinoma